Sagar Lonial Biography and Net Worth

Director of TG Therapeutics

Sagar Lonial was nominated for a position on our Board in April 2020. Dr. Lonial is an internationally recognized authority in multiple myeloma and lymphoma treatment and research and currently serves as Professor and Chair of the Department of Hematology and Medical Oncology at the Emory University School of Medicine, as well as the Chief Medical Officer at Winship Cancer Institute of Emory University. He is involved in numerous professional organizations including the American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation, as well as involved in research with the Multiple Myeloma Research Foundation (MMRF), the Lymphoma Research Foundation (LRF) and the Leukemia and Lymphoma Society (LLS). Dr. Lonial also serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group (ECOG) and as Chair of the Steering Committee for the Multiple Myeloma Research Consortium. He has authored or co-authored over 200 peer-reviewed publications. Dr. Lonial serves on the editorial board of the Journal of Clinical Oncology, Leukemia, is the myeloma editor for Clinical Lymphoma, Myeloma & Leukemia, and is the hematologic malignancies section editor for the journal Cancer. Dr. Lonial earned his medical degree from the University of Louisville School of Medicine and completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology and oncology at Emory University School of Medicine in Atlanta, Georgia.

What is Sagar Lonial's net worth?: The estimated net worth of Sagar Lonial is at least $4.20 million as of November 11th, 2024. Mr. Lonial owns 100,195 shares of TG Therapeutics stock worth more than $4,196,868 as of March 26th. This net worth approximation does not reflect any other investments that Mr. Lonial may own. Learn More about Sagar Lonial's net worth.
How do I contact Sagar Lonial?: The corporate mailing address for Mr. Lonial and other TG Therapeutics executives is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. TG Therapeutics can also be reached via phone at (212) 554-4484 and via email at ir@tgtxinc.com. Learn More on Sagar Lonial's contact information.
Has Sagar Lonial been buying or selling shares of TG Therapeutics?: Sagar Lonial has not been actively trading shares of TG Therapeutics within the last three months. Most recently, Sagar Lonial sold 5,000 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a transaction totalling $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares of the company's stock, valued at $3,049,935.80. Learn More on Sagar Lonial's trading history.
Who are TG Therapeutics' active insiders?: TG Therapeutics' insider roster includes Laurence Charney (Director), Yann Echelard (Director), Sagar Lonial (Director), Sean Power (CFO), and Michael Weiss (CEO). Learn More on TG Therapeutics' active insiders.
Are insiders buying or selling shares of TG Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 26,358 shares worth more than $781,496.86. The most recent insider tranaction occured on January, 6th when CFO Sean A Power sold 10,021 shares worth more than $285,899.13. Insiders at TG Therapeutics own 10.5% of the company. Learn More about insider trades at TG Therapeutics.
Information on this page was last updated on 1/6/2025.

Sagar Lonial Insider Trading History at TG Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/11/2024	Sell	5,000	$30.44	$152,200.00	100,195
6/23/2023	Sell	34,854	$23.37	$814,537.98	93,878

Sagar Lonial Buying and Selling Activity at TG Therapeutics

TG Therapeutics Company Overview

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Today's Range

Now: $41.89

$42.51

$42.92

50 Day Range

MA: $33.73

$28.53

$42.99

2 Week Range

Now: $41.89

$12.93

$43.32

Volume

26,961 shs

Average Volume

2,972,338 shs

Market Capitalization

$6.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.3